Cargando…

Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy

The results of a recently completed Phase III clinical trial suggest that concurrent chemoradiotherapy followed by tecemotide provides superior benefits to Stage IIIa and IIIb non-small cell lung carcinoma patients as compared with sequential chemoradiotherapy followed by tecemotide. These clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kao, Chiao-Jung, Wurz, Gregory T, Schröder, Andreas, Wolf, Michael, DeGregorio, Michael W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896473/ https://www.ncbi.nlm.nih.gov/pubmed/24498545 http://dx.doi.org/10.4161/onci.26285

Ejemplares similares

L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?
por: DeGregorio, Michael, et al.
Publicado: (2012)

Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model
por: Wurz, Gregory T, et al.
Publicado: (2013)

Cyclophosphamide mechanism of action in preclinical tecemotide studies
por: Hance, Ken, et al.
Publicado: (2013)

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
por: Wurz, Gregory T, et al.
Publicado: (2014)

A comprehensive breath test that confirms recent use of inhaled cannabis within the impairment window
por: DeGregorio, Michael W., et al.
Publicado: (2021)

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
por: Soe, Lin H, et al.
Publicado: (2013)

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
por: Wu, Yi-Long, et al.
Publicado: (2011)

Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells
por: Lutz, Manfred B, et al.
Publicado: (2014)

Indeterminacy of cannabis impairment and ∆(9)-tetrahydrocannabinol (∆(9)-THC) levels in blood and breath
por: Wurz, Gregory T., et al.
Publicado: (2022)

Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
por: Rekers, Nicolle H, et al.
Publicado: (2015)

Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ(8)-tetrahydrocannabinol: case studies
por: Wurz, Gregory T., et al.
Publicado: (2022)

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
por: Yang, Yan, et al.
Publicado: (2013)

The role of soluble CD40L in immunosuppression
por: Schlom, Jeffrey, et al.
Publicado: (2013)

Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma
por: Zhang, Mengxian, et al.
Publicado: (2012)

NKp44L: A new tool for fighting cancer
por: Vieillard, Vincent, et al.
Publicado: (2014)

Structure and function of a monocarboxylate transporter homolog specific for L-lactate
por: Bosshart, Patrick D., et al.
Publicado: (2019)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

The novel partnership of L-GILZ and p53: a new affair in cancer?
por: Ayroldi, Emira, et al.
Publicado: (2014)

Tumor microenvironment in NSCLC suppresses NK cells function
por: Cremer, Isabelle, et al.
Publicado: (2012)

A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
por: Nagato, Toshihiro, et al.
Publicado: (2014)

PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer
por: Schalper, Kurt A
Publicado: (2014)

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
por: Cartellieri, Marc, et al.
Publicado: (2013)

Engineering effective T-cell based antitumor immunity
por: Gruber, Thomas, et al.
Publicado: (2013)

Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2014)

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013)

Motolimod effectively drives immune activation in advanced cancer patients
por: Dietsch, Gregory N.
Publicado: (2016)

Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression
por: Deng, Liufu, et al.
Publicado: (2014)

SIN3B, the SASP, and pancreatic cancer
por: Cantor, David J, et al.
Publicado: (2014)

Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses
por: Goc, Jérémy, et al.
Publicado: (2014)

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial
por: Schimanski, Carl Christoph, et al.
Publicado: (2012)

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
por: Peng, Weiyi, et al.
Publicado: (2013)

Forging a link between oncogenic signaling and immunosuppression in melanoma
por: Khalili, Jahan S., et al.
Publicado: (2013)

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
por: Aranda, Fernando, et al.
Publicado: (2014)

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity
por: Hargadon, Kristian Michael
Publicado: (2015)

Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment
por: Mace, Thomas A, et al.
Publicado: (2013)

Tumor-infiltrating B cells: The ignored players in tumor immunology
por: Linnebacher, Michael, et al.
Publicado: (2012)

JmjC histone demethylases act as chromatin oxygen sensors
por: Batie, Michael, et al.
Publicado: (2019)

PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation
por: Spalinger, Marianne R., et al.
Publicado: (2018)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies
por: Verbrugge, Inge, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j84bnv0r7ocnetjc3fe4mllrhr